Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NGI-1 |
Synonyms | |
Therapy Description |
NGI-1 inhibits the activity of oligosacchyltransferase, which results in reduced N-linked glycosylation and may lead to decreased proliferation of tumor cells with dependence on receptor tyrosine kinase signaling (PMID: 27694802, PMID: 31511384). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NGI-1 | ML414 | NGI-1 inhibits the activity of oligosacchyltransferase, which results in reduced N-linked glycosylation and may lead to decreased proliferation of tumor cells with dependence on receptor tyrosine kinase signaling (PMID: 27694802, PMID: 31511384). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR1 amp | lung non-small cell carcinoma | predicted - sensitive | NGI-1 | Preclinical - Cell culture | Actionable | In a preclinical study, NGI-1 inhibited FGFR1 phosphorylation and proliferation of a FGFR1-amplified cell line dependent on FGFR1 signaling in culture, however, did not inhibit proliferation of an FGFR1-amplified cell line not dependent on FGFR1 signaling (PMID: 27694802). | 27694802 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|